Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 45-49    DOI: 10.31083/j.ejgo.2021.01.2130
Original Research Previous articles | Next articles
Cytoplasmic pollen extract for treatment of menopausal symptoms in breast cancer patients: a case series report
Aldo Iop1, *(), Pamela Driol1, Alessandra Zacchia1, Manuela Miscoria1
1Oncology Unit, AAS2 Bassa Friulana Isontina, 33053, Italy
Download:  PDF(670KB)  ( 86 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Menopausal symptoms, such as hot flushes (HFs), night sweats, vaginal dryness, psychological symptoms, and sexual dysfunction are a significant issue in breast cancer (BC) survivors, especially in those with hormone receptor-positive (HR+) subtype. Since hormone replacement therapy (HRT) is not indicated in these patients due to its estrogenic activity, we sought to investigate the role of cytoplasmic pollen extract (Femal®) with non-estrogenic effects as an adjuvant treatment in BC women. Methods: This case series study included 12 women with HR+, eight with Luminal A and four with Luminal B cancers, with a median age of 47 years (range 37-53) who received cytoplasmic pollen extract for 3 months. Menopause symptomatology was monitored through the Menopause Rating Scale (MRS) at the beginning of the treatment (T0) and at 90 days (T3). Tolerance was evaluated by the European Organization for Research and Treatment of Cancer (EORTC) score. Results: After 3 months of treatment, all cases had an improvement in HFs, cardiac symptoms, irritability and anxiety symptoms. No side effects were found. Tolerance and compliance were excellent during the study. Conclusions: This observational study suggests that cytoplasmic pollen extract is well tolerated when administered to BC (HR+) women with contraindications to HRT together with a positive impact on the patient's menopausal related symptoms. However, longer follow-up and future randomized studies are needed.
Key words:  Cytoplasmic pollen extract      Menopausal symptoms      Breast cancer patients      Quality of life      Non-hormonal therapy     
Submitted:  12 May 2020      Revised:  15 October 2020      Accepted:  26 October 2020      Published:  15 February 2021     
*Corresponding Author(s):  Aldo Iop     E-mail:  aldo.iop@aas2.sanita.fvg.it

Cite this article: 

Aldo Iop, Pamela Driol, Alessandra Zacchia, Manuela Miscoria. Cytoplasmic pollen extract for treatment of menopausal symptoms in breast cancer patients: a case series report. European Journal of Gynaecological Oncology, 2021, 42(1): 45-49.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2130     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/45

[1] Rossella E. Nappi, Nicoletta Biglia, Ettore Cicinelli, Tiziana Di Paolantonio, Stefano Luisi, Massimo Stomati, Paola Villa, on behalf of the EVES study investigators. The European Vulvovaginal Epidemiological Survey (EVES) in Italy. Impact of vulvovaginal atrophy on the quality of life and sexual function in breast cancer survivors[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 38-44.
[2] Yu-Yi Ou, Shuang Liu, Jian-Lan Zhang, Hui-Zhi Yuan, Yu-Hua Zheng. Effects of whole-course standardized nursing and humanistic care on the sleep condition and quality of life of elderly patients undergoing hysterectomy for cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 154-160.
[3] A. Rossi, C.E. Garber, M. Ortiz, V. Shankar, D.Y. Kuo, N.S. Nevadunsky. Sustained effects of theory-based physical activity intervention for socioeconomically diverse obese endometrial cancer survivors: A Longitudinal analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 343-351.
[4] Chunyu Xu, Chun Fang, Zhiguo Zhang, Jinwei Miao. Effects of community intervention on quality of life in women with gynecological cancers[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 948-950.
No Suggested Reading articles found!